This is quite a list of potential uses...some of which ar every big $$$. For example RA is huge, MS is huge.
"The allowed claims cover the use of epratuzumab, the Company's proprietary humanized anti-CD22 monoclonal antibody, and other anti-CD22 antibodies, alone and in combination with other therapeutics, such as antibodies, cytokines, or drugs, for the treatment of a wide range of autoimmune diseases that include systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, diabetes mellitus, and ulcerative colitis. "
"Value of this drug, if brought to market, should be about $4 Billion in annual sales or 10 times the current market cap. We could see a $50 price on this stock soon, especially with fast track status by the FDA. "